Skip to main content
Equibles
RLYB logo

RLYB · Rallybio Corp

Track RLYB — free

Use RLYB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RLYB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.08 +0.32 (+1.91%) At close · Oct 2
Rebalance outlook locked
Market Cap
$88.26M
Shares
5.31M
Volume · Oct 2 7853 Avg daily vol (3M) 22.77K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$17.08 Open$16.69 Day$16.69–17.22 52W close$4.09–17.22 Avg vol 30d10K Short int56K · 1.0% float · 5.0d Short vol18% Last earningsMar 13, 2025 DataJul 2021–Oct 2026 Filing10-Q · Aug 6

Up next

Latest filing: 10-Q
filed Aug 6, 2026
Q4 2024 earnings call transcript
call held Mar 13, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$646,000
Trailing 12 months
Net income (TTM)
$45.55M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-4,291.5%
Trailing 12 months
P / E (TTM)
2.2
Trailing earnings · reciprocal yield 46.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$92.85M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.0%
Latest settlement · 5.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bearish Fundamentals Strong Quant / Vol High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +44%
above
Price vs 50-day avg +2%
above
RSI (14) 54
neutral
MACD trend Negative
52-week position 99%
near high
Momentum
relative strength
Very Strong
1-month return +1%
trailing
6-month return +106%
trailing
YTD return +211%
this year
Relative strength +94%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.05% of float · ▲ +1.1% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
37 holders — near 3-yr low, contrarian setup
Squeeze score 49
elevated · 0–100
Fundamentals
Strong
Revenue growth +35%
Y/Y
EPS growth +85%
Y/Y
Free cash flow $-29.8M
Valuation P/E 2.1
below peers
Quant / Vol
risk profile
High
Volatility 88%
annualized · 1-yr
Max drawdown −31%
past year
ATR 2.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+44% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
54 Neutral
MACD trend
Negative Bearish
52-week position
99% Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.05% of float · ▲ +1.1% MoM · 5.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
37 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $4 Now $17 · 99% Range high $17
vs 200-day avg +44% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RLYB
Rallybio Corp
this stock
$88.26M — +34.9% 2.1 1.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
37
% held
76.6%
Net QoQ
-601.2K sh
Top holder
ADAR1 Capital Management,…
Held Float
View
Held by Funds
Fund positions
16
View
Short & Settlement
Short Interest Rising
Shares short
55.6K
Days to cover
5.0d
Change
+613 sh
View
Short Volume
Short vol %
18%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
12
Value
$203
As of
Sep 4, 2026
View
Off-Exchange
Off-exchange %
31.8%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$858.0K
Net income (FY)
$-9.0M
EPS diluted
$-1.59
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 9, 2026
This year
10
View
Exempt Offerings
Offering
$6.6M
Filed
Apr 22, 2024
View
Earnings & Events
Webcasts
Last webcast
Mar 13, 2025
View

Performance

5D 20D 120D MTD YTD
RLYB +2.8% +1.2% +105.8% -0.7% +211.2%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +3.0% +1.7% +93.6% -1.6% +198.4%
Key facts CIK 1739410 CUSIP 75120L209 13F (30d) 1 filings 1 filers Visit website Investor relations